ketanserin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
serotonin receptor antagonists (mostly 5-HT2) 1524 74050-98-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • R 41 468
  • ketanserin
  • ketensin
  • suffrexal
  • ketanserin tartrate hydrate
  • ketanserin tartrate
  • R 41468
A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
  • Molecular weight: 395.43
  • Formula: C22H22FN3O3
  • CLOGP: 2.92
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 69.72
  • ALOGS: -3.40
  • ROTB: 5

Drug dosage:

DoseUnitRoute
40 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.05 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.78 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.932 Moderate 0.68
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.693 Moderate 0.68
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 39.902 10^-6 cm/s Moderate 0.68
dh-clint Dog hepatocyte intrinsic clearance 11.588 uL/min/10^6 cells Moderate 0.68
dppb Dog plasma protein binding (% unbound) 10.910 % Moderate 0.68
fcs-ppb Fetal calf serum protein binding (% unbound) 25.090 % Moderate 0.68
herg hERG pIC50 5.686 pIC50 Moderate 0.68
hh-clint Human hepatocyte intrinsic clearance 23.605 uL/min/10^6 cells Moderate 0.68
hlm-clint Human liver microsomal intrinsic clearance 21.528 uL/min/mg protein Moderate 0.68
hppb Human plasma protein binding (% unbound) 7.660 % Moderate 0.68
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,KIT,MAP3K21,MAP3K7,MAPK10,MAPK7,MARK4,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK 37
kinase-selectivity-class ACVR2B,AXL,BRAF,CAMK2D,CDK9,EIF2AK3,GRK2,MAPK7,MARK4,SIK2,SIK3,STK33,TEK,TTK 14
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.081 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.559 Moderate 0.68
mh-clint Mouse hepatocyte intrinsic clearance 42.462 Moderate 0.68
mppb Mouse plasma protein binding (% unbound) 13.040 Moderate 0.68
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 5.728 Moderate 0.68
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 17.120 % Moderate 0.68
rat-kpuu-brain Rat brain Kpuu 0.252 % High 1
rh-clint Rat hepatocyte intrinsic clearance 63.387 uL/min/10^6 cells Moderate 0.68
rh-fuinc Rat hepatocyte fraction unbound in incubation 61.860 % Moderate 0.68
rppb Rat plasma protein binding (% unbound) 7.610 % Moderate 0.68
solubility-dd Solubility at pH 7.4 in DMSO 15.276 uM Moderate 0.68

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02KD01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
OTHER ANTIHYPERTENSIVES
Serotonin antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D012702 Serotonin Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:37890 ฮฑ-adrenergic antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:176497 geroprotector

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.58 acidic
pKa2 8.02 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR ANTAGONIST Ki 5 IUPHAR
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 6.70 IUPHAR
5-hydroxytryptamine receptor 2A GPCR Ki 9.70 CHEMBL
D(1A) dopamine receptor GPCR ANTAGONIST Ki 6.70 IUPHAR
D(2) dopamine receptor GPCR Ki 6.62 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor IC50 9 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.97 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 7.50 IUPHAR
5-hydroxytryptamine receptor 6 GPCR Ki 5.55 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.50 IUPHAR
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
Alpha-2B adrenergic receptor GPCR Ki 6.70 PDSP
D(1B) dopamine receptor GPCR ANTAGONIST Ki 5.60 IUPHAR
Histamine H1 receptor GPCR Ki 8.75 PDSP
5-hydroxytryptamine receptor 1B GPCR IC50 5.19 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 6.59 CHEMBL
Adenosine receptor A3 GPCR IC50 8.57 CHEMBL
D(4) dopamine receptor GPCR Ki 8.46 CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 7.80 IUPHAR
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 5A GPCR ANTAGONIST Ki 4.70 IUPHAR
5-hydroxytryptamine receptor 1F GPCR Ki 8.90 PDSP
Synaptic vesicular amine transporter Transporter Ki 6.16 WOMBAT-PK
Chromaffin granule amine transporter Transporter INHIBITOR Ki 5.80 IUPHAR
5-hydroxytryptamine receptor 1B GPCR Ki 5.72 CHEMBL
Histamine H1 receptor GPCR Ki 8 CHEMBL
D(2) dopamine receptor GPCR Ki 6.44 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.74 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.33 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.70 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.40 IUPHAR
5-hydroxytryptamine receptor 2C GPCR Ki 7.30 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 7.82 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 9.40 CHEMBL
5-hydroxytryptamine receptor 1B GPCR ANTAGONIST Ki 8.30 IUPHAR
Synaptic vesicular amine transporter Transporter IC50 7 CHEMBL

External reference:

IDSource
N0000167209 NUI
D02363 KEGG_DRUG
C0022616 UMLSCUI
CHEBI:6123 CHEBI
UYX PDB_CHEM_ID
CHEMBL51 ChEMBL_ID
D007650 MESH_DESCRIPTOR_UI
DB12465 DRUGBANK_ID
3822 PUBCHEM_CID
88 IUPHAR_LIGAND_ID
5087 INN_ID
83846-83-7 SECONDARY_CAS_RN
97F9DE4CT4 UNII
6131 RXNORM
005934 NDDF
441818008 SNOMEDCT_US
442141001 SNOMEDCT_US
CHEMBL1256709 ChEMBL_ID
97F9DE4CT4 INXIGHT DRUGS

Pharmaceutical products:

None